Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 May 17;17(1):248.
doi: 10.1186/s13063-016-1374-5.

Tian Jiu therapy for allergic rhinitis: study protocol for a randomized controlled trial

Wai Kun  1   2 , Linda L D Zhong  1   2 , Liang Dai  1   2 , Chung-Wah Cheng  1   2 , Ai-Ping Lu  1   2 , Zhao-Xiang Bian  3   4
Affiliations
Randomized Controlled Trial

Tian Jiu therapy for allergic rhinitis: study protocol for a randomized controlled trial

Wai Kun et al. Trials. .

Abstract

Background: Allergic rhinitis (AR) is one of the most common allergic diseases. The conventional treatments of allergic rhinitis are oral anti-histamines, the use of intranasal corticosteroids, and immunotherapy. Dissatisfied with the ineffectiveness and side effects of these treatments, substantial numbers of patients are turning to alternative treatments like Chinese herbal medicine, particularly Tian Jiu (TJ). TJ is a form of moxibustion in which herbal patches are applied to specific acupoints on the skin. This study aims to investigate the efficacy and safety of TJ in the treatment of allergic rhinitis.

Methods/design: This will be a prospective, randomized, single-blinded, controlled trial in patients with AR. After a 1-week run-in period, eligible subjects will be randomly assigned to the TJ group, placebo-control group or waitlist-control group. The TJ and placebo-control groups will undergo a 4-week treatment with one session per week and one 4-week post-treatment follow-up. Participants in the waitlist-control group will not receive any treatment during the first 4 weeks but will be required to be assessed. The primary outcome will be the change in the weekly average of the Total Nasal Symptom Score recorded from baseline to the end of treatment. The secondary outcomes will be change in symptoms and change in need for medication between baseline and the end of treatment by using the Rhinitis Quality of Life Questionnaire. Rescue medication (RM) needs will be measured using an RM score, comprising the weekly sum of daily assessments and any form of systemic steroids for allergic rhinitis.

Discussion: This study will be the first study to compare TJ treatment for allergic rhinitis with a placebo-control group, and a waitlist-control group. The investigation of TJ for allergic rhinitis will also suggest recommendations for clinical practice. The results of this study are expected to provide consolidated evidence for the effectiveness and safety of TJ for the treatment of patients with allergic rhinitis.

Trial registration: NCT02470845 (17 May 2015).

Keywords: Allergic rhinitis; Chinese herbal medicine; Randomized controlled trial; Tian Jiu.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Participant flowchart
Fig 2
Fig 2
Schedule of enrollment, intervention and assessment
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Anonymous Worldwide variation in prevalence of symptoms of asthma, allergic rhino conjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351:1225–32. doi: 10.1016/S0140-6736(97)07302-9. - DOI - PubMed
    1. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 2001;107:3–8. doi: 10.1067/mai.2001.112262. - DOI - PubMed
    1. Van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy. 2000;55:116–34. doi: 10.1034/j.1398-9995.2000.00526.x. - DOI - PubMed
    1. Schoenwetter WF, Dupclay L, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin. 2004;20:305–17. doi: 10.1185/030079903125003053. - DOI - PubMed
    1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24:758–64. doi: 10.1183/09031936.04.00013904. - DOI - PubMed

Publication types

Associated data